Does EBV alter the pathogenesis of malaria?

Parasite Immunology

Volumn 37, Issue 9, 2015, Pages 433-445

  Matar, C G ^a   Jacobs, N T ^a   Speck, S H ^a,b   Lamb, T J ^a,d   Moormann, A M ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Rollins Research Center   (United States)

Author keywords

Animal models; Co infection; Epidemiologic studies; Immunity

Indexed keywords

AFRICA SOUTH OF THE SAHARA; CD8+ T LYMPHOCYTE; DISEASES; EPSTEIN BARR VIRUS; GAMMAHERPESVIRINAE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MALARIA FALCIPARUM; MIXED INFECTION; NONHUMAN; PATHOGENESIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; ACUTE DISEASE; ANIMAL; BURKITT LYMPHOMA; CHILD; DISEASE MODEL; EPSTEIN-BARR VIRUS INFECTIONS; IMMUNOLOGY; MALARIA, FALCIPARUM; PARASITOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

CYTOKINE;

ACUTE DISEASE; AFRICA SOUTH OF THE SAHARA; ANIMALS; BURKITT LYMPHOMA; CHILD; COINFECTION; CYTOKINES; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MALARIA, FALCIPARUM; T-LYMPHOCYTES;

EID: 84941036267     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12212     Document Type: Review

References (151)

1. World Health Organization. Global Malaria Programme. World Malaria Report 2012. Geneva, World Health Organization, 2012: iv, 249pp.
2. Miller LH, Baruch DI, Marsh K & Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415: 673-679.
3. Langhorne J, Ndungu FM, Sponaas AM & Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9: 725-732.
4. Greenwood B, Marsh K & Snow R. Why do some African children develop severe malaria? Parasitol Today 1991; 7: 277-281.
5. Riley EM & Stewart VA. Immune mechanisms in malaria: new insights in vaccine development. Nat Med 2013; 19: 168-178.
6. Biggar RJ, Henle W, Fleisher G, etal. Primary Epstein-Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection. Int J Cancer 1978; 22: 239-243.
7. Biggar RJ, Henle G, Bocker J, etal. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int J Cancer 1978; 22: 244-250.
8. Henle G & Henle W. Observations on childhood infections with the Epstein-Barr virus. J Infect Dis 1970; 121: 303-310.
9. Piriou E, Asito AS, Sumba PO, etal. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis 2012; 205: 906-913.
10. Moormann AM, Chelimo K, Sumba OP, etal. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005; 191: 1233-1238.
11. Moormann AM, Snider CJ & Chelimo K. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis 2011; 24: 435-441.
12. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218-223.
13. Moormann AM, Chelimo K, Sumba PO, etal. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 2007; 195: 799-808.
14. Moormann AM, Heller KN, Chelimo K, etal. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009; 124: 1721-1726.
15. Whittle HC, Brown J, Marsh K, etal. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 1984; 312: 449-450.
16. Njie R, Bell AI, Jia H, etal. The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 2009; 199: 31-38.
17. Snider CJ, Cole SR, Chelimo K, etal. Recurrent Plasmodium falciparum malaria infections in Kenyan children diminish T-cell immunity to Epstein Barr virus lytic but not latent antigens. PLoS One 2012; 7: e31753.
18. Chene A, Donati D, Guerreiro-Cacais AO, etal. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 2007; 3: e80.
19. Chene A, Nylen S, Donati D, etal. Effect of acute Plasmodium falciparum malaria on reactivation and shedding of the eight human herpes viruses. PLoS One 2011; 6: e26266.
20. Piriou E, Kimmel R, Chelimo K, etal. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. J Med Virol 2009; 81: 1088-1093.
21. Cohen S, Mc GI & Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192: 733-737.
22. Sabchareon A, Burnouf T, Ouattara D, etal. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45: 297-308.
23. Bowen TJ, Wedgwood RJ, Ochs HD & Henle W. Transient immunodeficiency during asymptomatic Epstein-Barr virus infection. Pediatrics 1983; 71: 964-967.
24. Junker AK, Ochs HD, Clark EA, Puterman ML & Wedgwood RJ. Transient immune deficiency in patients with acute Epstein-Barr virus infection. Clin Immunol Immunopathol 1986; 40: 436-446.
25. Holder B, Miles DJ, Kaye S, etal. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants. PLoS One 2010; 5: e14013.
26. Dobano C, Rogerson SJ, Mackinnon MJ, etal. Differential antibody responses to Plasmodium falciparum merozoite proteins in Malawian children with severe malaria. J Infect Dis 2008; 197: 766-774.
27. Leoratti FM, Durlacher RR, Lacerda MV, etal. Pattern of humoral immune response to Plasmodium falciparum blood stages in individuals presenting different clinical expressions of malaria. Malar J 2008; 7: 186.
28. Yone CL, Kube D, Kremsner PG & Luty AJ. Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2006; 100: 669-676.
29. Mueller I, Schoepflin S, Smith TA, etal. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci USA 2012; 109: 10030-10035.
30. Smith T, Beck HP, Kitua A, etal. Age dependence of the multiplicity of Plasmodium falciparum infections and of other malariological indices in an area of high endemicity. Trans R Soc Trop Med Hyg 1999; 93(Suppl 1): 15-20.
31. Rochford R, Cannon MJ & Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol 2005; 3: 182-187.
32. Killick-Kendrick R & Peters W. Rodent Malaria. London, Academic Press, 1978.
33. Perkins DJ, Weinberg JB & Kremsner PG. Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. J Infect Dis 2000; 182: 988-992.
34. Malaguarnera L, Imbesi RM, Pignatelli S, etal. Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite Immunol 2002; 24: 387-389.
35. Luty AJ, Perkins DJ, Lell B, etal. Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun 2000; 68: 3909-3915.
36. Stevenson MM, Tam MF, Wolf SF & Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol 1995; 155: 2545-2556.
37. Urban BC, Ferguson DJ, Pain A, etal. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400: 73-77.
38. Giusti P, Urban BC, Frascaroli G, etal. Plasmodium falciparum-infected erythrocytes and beta-hematin induce partial maturation of human dendritic cells and increase their migratory ability in response to lymphoid chemokines. Infect Immun 2011; 79: 2727-2736.
39. Mukherjee P & Chauhan VS. Plasmodium falciparum-free merozoites and infected RBCs distinctly affect soluble CD40 ligand-mediated maturation of immature monocyte-derived dendritic cells. J Leukoc Biol 2008; 84: 244-254.
40. Elliott SR, Spurck TP, Dodin JM, etal. Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect Immun 2007; 75: 3621-3632.
41. Ing R, Segura M, Thawani N, Tam M & Stevenson MM. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J Immunol 2006; 176: 441-450.
42. Ruedl C, Rieser C, Bock G, Wick G & Wolf H. Phenotypic and functional characterization of CD11c+ dendritic cell population in mouse Peyer's patches. Eur J Immunol 1996; 26: 1801-1806.
43. de Walick S, Amante FH, McSweeney KA, etal. Cutting edge: conventional dendritic cells are the critical APC required for the induction of experimental cerebral malaria. J Immunol 2007; 178: 6033-6037.
44. Perry JA, Rush A, Wilson RJ, Olver CS & Avery AC. Dendritic cells from malaria-infected mice are fully functional APC. J Immunol 2004; 172: 475-482.
45. Artavanis-Tsakonas K, Eleme K, McQueen KL, etal. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J Immunol 2003; 171: 5396-5405.
46. Chelimo K, Embury PB, Sumba PO, etal. Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One 2011; 6: e24852.
47. D'Ombrain MC, Hansen DS, Simpson KM & Schofield L. gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria. Eur J Immunol 2007; 37: 1864-1873.
48. Troye-Blomberg M, Worku S, Tangteerawatana P, etal. Human gamma delta T cells that inhibit the invitro growth of the asexual blood stages of the Plasmodium falciparum parasite express cytolytic and proinflammatory molecules. Scand J Immunol 1999; 50: 642-650.
49. Freitas do Rosario AP, Lamb T, Spence P, etal. IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J Immunol 2012; 188: 1178-1190.
50. D'Ombrain MC, Robinson LJ, Stanisic DI, etal. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis 2008; 47: 1380-1387.
51. Imai T, Shen J, Chou B, etal. Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain. Eur J Immunol 2010; 40: 1053-1061.
52. Ing R & Stevenson MM. Dendritic cell and NK cell reciprocal cross talk promotes gamma interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect Immun 2009; 77: 770-782.
53. Lundie RJ, de Koning-Ward TF, Davey GM, etal. Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci USA 2008; 105: 14509-14514.
54. Seixas EM & Langhorne J. gammadelta T cells contribute to control of chronic parasitemia in Plasmodium chabaudi infections in mice. J Immunol 1999; 162: 2837-2841.
55. Osier FH, Fegan G, Polley SD, etal. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76: 2240-2248.
56. van der Heyde HC, Huszar D, Woodhouse C, Manning DD & Weidanz WP. The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. J Immunol 1994; 152: 4557-4562.
57. Ndungu FM, Cadman ET, Coulcher J, etal. Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog 2009; 5: e1000690.
58. Stephens R, Ndungu FM & Langhorne J. Germinal centre and marginal zone B cells expand quickly in a second Plasmodium chabaudi malaria infection producing mature plasma cells. Parasite Immunol 2009; 31: 20-31.
59. von der Weid T, Honarvar N & Langhorne J. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J Immunol 1996; 156: 2510-2516.
60. Francois S, Vidick S, Sarlet M, etal. Illumination of murine gammaherpesvirus-68 cycle reveals a sexual transmission route from females to males in laboratory mice. PLoS Pathog 2013; 9: e1003292.
61. Isaacs R. Chronic infectious mononucleosis. Blood 1948; 3: 858-861.
62. Sixbey JW, Lemon SM & Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986; 2: 1122-1124.
63. Israele V, Shirley P & Sixbey JW. Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis 1991; 163: 1341-1343.
64. Damania B & Pipas JM. DNA Tumor Viruses. New York, Springer Science + Business Media, 2009: xxvi, 794 p., 4 p. of plates p.
65. Collins CM & Speck SH. Tracking murine gammaherpesvirus 68 infection of germinal center B cells invivo. PLoS One 2012; 7: e33230.
66. Willer DO & Speck SH. Long-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells invivo. J Virol 2003; 77: 8310-8321.
67. Weck KE, Kim SS, Virgin HI & Speck SH. B cells regulate murine gammaherpesvirus 68 latency. J Virol 1999; 73: 4651-4661.
68. Schaade L, Kleines M & Hausler M. Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein-Barr virus infections in childhood. J Clin Microbiol 2001; 39: 3902-3905.
69. Cardin RD, Brooks JW, Sarawar SR & Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996; 184: 863-871.
70. Christensen JP, Cardin RD, Branum KC & Doherty PC. CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. Proc Natl Acad Sci USA 1999; 96: 5135-5140.
71. Dias P, Giannoni F, Lee LN, etal. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions. J Virol 2010; 84: 8241-8249.
72. McClellan KB, Gangappa S & Speck SH. Virgin HWt. Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses. PLoS Pathog 2006; 2: e58.
73. Sangster MY, Topham DJ, D'Costa S, etal. Analysis of the virus-specific and nonspecific B cell response to a persistent B-lymphotropic gammaherpesvirus. J Immunol 2000; 164: 1820-1828.
74. Barton ES, Lutzke ML & Rochford R. Virgin HWt. Alpha/beta interferons regulate murine gammaherpesvirus latent gene expression and reactivation from latency. J Virol 2005; 79: 14149-14160.
75. Guggemoos S, Hangel D, Hamm S, etal. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008; 180: 438-443.
76. Gargano LM, Moser JM & Speck SH. Role for MyD88 signaling in murine gammaherpesvirus 68 latency. J Virol 2008; 82: 3853-3863.
77. Pasare C & Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005; 438: 364-368.
78. Mandal P, Krueger BE, Oldenburg D, etal. A gammaherpesvirus cooperates with interferon-alpha/beta-induced IRF2 to halt viral replication, control reactivation, and minimize host lethality. PLoS Pathog 2011; 7: e1002371.
79. Matar CG, Anthony NR, O'Flaherty BM, etal. Gammaherpesvirus co-infection with malaria suppresses anti-parasitic humoral immunity. PLoS Pathog 2011; 7: e1002371. doi: 10.1371/journal.ppat.1002371.
80. Haque A, Rachinel N, Quddus MR, etal. Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection. Clin Exp Immunol 2004; 138: 396-404.
81. Getahun A, Smith MJ, Kogut I, van Dyk LF & Cambier JC. Retention of anergy and inhibition of antibody responses during acute gamma herpesvirus 68 infection. J Immunol 2012; 189: 2965-2974.
82. Yager EJ, Szaba FM, Kummer LW, etal. gamma-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol 2009; 22: 67-72.
83. Barton ES, White DW, Cathelyn JS, etal. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007; 447: 326-329.
84. Sponaas AM, Freitas do Rosario AP, Voisine C, etal. Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood 2009; 114: 5522-5531.
85. Stevenson MM, Huang DY, Podoba JE & Nowotarski ME. Macrophage activation during Plasmodium chabaudi AS infection in resistant C57BL/6 and susceptible A/J mice. Infect Immun 1992; 60: 1193-1201.
86. Cunnington AJ, Riley EM & Walther M. Stuck in a rut? Reconsidering the role of parasite sequestration in severe malaria syndromes. Trends Parasitol 2013; 29: 585-592.
87. Paludan SR, Bowie AG, Horan KA & Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat Rev Immunol 2011; 11: 143-154.
88. Hwang S, Kim KS, Flano E, etal. Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe 2009; 5: 166-178.
89. Rodrigues L, Filipe J, Seldon MP, etal. Termination of NF-kappaB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase. EMBO J 2009; 28: 1283-1295.
90. Dong X & Feng P. Murine-gamma herpesvirus 68 hijacks MAVS and IKKbeta to abrogate NFkappaB activation and antiviral cytokine production. PLoS Pathog 2011; 7: e1002336.
91. Zimring JC, Goodbourn S & Offermann MK. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol 1998; 72: 701-707.
92. Gao SJ, Boshoff C, Jayachandra S, etal. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997; 15: 1979-1985.
93. Chatterjee M, Osborne J, Bestetti G, Chang Y & Moore PS. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002; 298: 1432-1435.
94. Wies E, Hahn AS, Schmidt K, etal. The Kaposi's sarcoma-associated Herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. J Biol Chem 2009; 284: 8525-8538.
95. Hahn AM, Huye LE, Ning S, Webster-Cyriaque J & Pagano JS. Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J Virol 2005; 79: 10040-10052.
96. Wang JT, Doong SL, Teng SC, etal. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J Virol 2009; 83: 1856-1869.
97. Barton E, Mandal P & Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011; 29: 351-397.
98. Parroche P, Lauw FN, Goutagny N, etal. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007; 104: 1919-1924.
99. Wu X, Gowda NM, Kumar S & Gowda DC. Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J Immunol 2010; 184: 4338-4348.
100. Haque A, Best SE, Ammerdorffer A, etal. Type I interferons suppress CD4(+) T-cell-dependent parasite control during blood-stage Plasmodium infection. Eur J Immunol 2011; 41: 2688-2698.
101. Voisine C, Mastelic B, Sponaas AM & Langhorne J. Classical CD11c+ dendritic cells, not plasmacytoid dendritic cells, induce T cell responses to Plasmodium chabaudi malaria. Int J Parasitol 2010; 40: 711-719.
102. Tarumi T, Sawada K, Sato N, etal. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995; 23: 1310-1318.
103. Vigario AM, Belnoue E, Gruner AC, etal. Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J Immunol 2007; 178: 6416-6425.
104. Essers MA, Offner S, Blanco-Bose WE, etal. IFNalpha activates dormant haematopoietic stem cells invivo. Nature 2009; 458: 904-908.
105. Sato T, Onai N, Yoshihara H, etal. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 2009; 15: 696-700.
106. Binder D, Fehr J, Hengartner H & Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med 1997; 185: 517-530.
107. Lamikanra AA, Brown D, Potocnik A, etal. Malarial anemia: of mice and men. Blood 2007; 110: 18-28.
108. Hardy GA, Sieg S, Rodriguez B, etal. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 2013; 8: e56527.
109. Davenport GC, Hittner JB, Were T, Ong'echa JM & Perkins DJ. Relationship between inflammatory mediator patterns and anemia in HIV-1 positive and exposed children with Plasmodium falciparum malaria. Am J Hematol 2012; 87: 652-658.
110. Orish VN, Onyeabor OS, Boampong JN, etal. The effects of malaria and HIV co-infection on hemoglobin levels among pregnant women in Sekondi-Takoradi, Ghana. Int J Gynaecol Obstet 2013; 120: 236-239.
111. Smith CM, Gill MB, May JS & Stevenson PG. Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells. PLoS One 2007; 2: e1048.
112. Li L, Liu D, Hutt-Fletcher L, etal. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002; 99: 3725-3734.
113. Rangaswamy US & Speck SH. Murine gammaherpesvirus M2 protein induction of IRF4 via the NFAT pathway leads to IL-10 expression in B cells. PLoS Pathog 2014; 10: e1003858.
114. Siegel AM, Herskowitz JH & Speck SH. The MHV68M2 protein drives IL-10 dependent B cell proliferation and differentiation. PLoS Pathog 2008; 4: e1000039.
115. Miyazaki I, Cheung RK & Dosch HM. Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 1993; 178: 439-447.
116. Saraiva M & O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-181.
117. Munn DH & Mellor AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34: 137-143.
118. Kim SK & Welsh RM. Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections. J Immunol 2004; 172: 3139-3150.
119. Liu H, Andreansky S, Diaz G, etal. Quantitative analysis of long-term virus-specific CD8+-T-cell memory in mice challenged with unrelated pathogens. J Virol 2003; 77: 7756-7763.
120. Guermonprez P, Helft J, Claser C, etal. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19: 730-738.
121. Belnoue E, Potter SM, Rosa DS, etal. Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria. Parasite Immunol 2008; 30: 544-553.
122. Villegas-Mendez A, Greig R, Shaw TN, etal. IFN-gamma-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. J Immunol 2012; 189: 968-979.
123. Chang WL, Jones SP, Lefer DJ, etal. CD8(+)-T-cell depletion ameliorates circulatory shock in Plasmodium berghei-infected mice. Infect Immun 2001; 69: 7341-7348.
124. Van den Steen PE, Geurts N, Deroost K, etal. Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am J Respir Crit Care Med 2010; 181: 957-968.
125. Haque A, Best SE, Amante FH, etal. High parasite burdens cause liver damage in mice following Plasmodium berghei ANKA infection independently of CD8(+) T cell-mediated immune pathology. Infect Immun 2011; 79: 1882-1888.
126. Mayor A, Bir N, Sawhney R, etal. Receptor-binding residues lie in central regions of Duffy-binding-like domains involved in red cell invasion and cytoadherence by malaria parasites. Blood 2005; 105: 2557-2563.
127. Mo M, Lee HC, Kotaka M, etal. The C-terminal segment of the cysteine-rich interdomain of Plasmodium falciparum erythrocyte membrane protein 1 determines CD36 binding and elicits antibodies that inhibit adhesion of parasite-infected erythrocytes. Infect Immun 2008; 76: 1837-1847.
128. Belnoue E, Kayibanda M, Vigario AM, etal. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol 2002; 169: 6369-6375.
129. Piva L, Tetlak P, Claser C, etal. Cutting edge: Clec9A+ dendritic cells mediate the development of experimental cerebral malaria. J Immunol 2012; 189: 1128-1132.
130. Coleman CB, Wohlford EM, Smith NA, etal. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol 2015; 89: 2301-2312.
131. Donati D, Zhang LP, Chene A, etal. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun 2004; 72: 5412-5418.
132. Pichyangkul S, Yongvanitchit K, Kum-arb U, etal. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol 2004; 172: 4926-4933.
133. Gabrielsen AA Jr & Jensen JB. Mitogenic activity of extracts from continuous cultures of Plasmodium falciparum. Am J Trop Med Hyg 1982; 31(Pt 1): 441-448.
134. Greenwood BM. Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria and trypanosomiasis. Lancet 1974; 1: 435-436.
135. Ishikawa H & Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455: 674-678.
136. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T & Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion invitro, but act in cooperation with monocytes. J Exp Med 1990; 172: 1633-1641.
137. Rovira-Vallbona E, Moncunill G, Bassat Q, etal. Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case-control study. Malar J 2012; 11: 181.
138. Gupta S, Snow RW, Donnelly CA, Marsh K & Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999; 5: 340-343.
139. Hadinoto V, Shapiro M, Greenough TC, etal. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008; 111: 1420-1427.
140. Vinetz JM, Kumar S, Good MF, etal. Adoptive transfer of CD8+ T cells from immune animals does not transfer immunity to blood stage Plasmodium yoelii malaria. J Immunol 1990; 144: 1069-1074.
141. Langhorne J, Simon-Haarhaus B & Meding SJ. The role of CD4+ T cells in the protective immune response to Plasmodium chabaudi invivo. Immunol Lett 1990; 25: 101-107.
142. van der Heyde HC, Manning DD, Roopenian DC & Weidanz WP. Resolution of blood-stage malarial infections in CD8+ cell-deficient beta 2-m0/0 mice. J Immunol 1993; 151: 3187-3191.
143. Yanez DM, Manning DD, Cooley AJ, Weidanz WP & van der Heyde HC. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J Immunol 1996; 157: 1620-1624.
144. Claser C, Malleret B, Gun SY, etal. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS ONE 2011; 6: e18720.
145. Nunes JK, Starnbach MN & Wirth DF. Secreted antibody is required for immunity to Plasmodium berghei. Infect Immun 2009; 77: 414-418.
146. Aucan C, Walley AJ, Hennig BJ, etal. Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun 2003; 4: 275-282.
147. Kempaiah P, Anyona SB, Raballah E, etal. Reduced interferon (IFN)-alpha conditioned by IFNA2 (-173) and IFNA8 (-884) haplotypes is associated with enhanced susceptibility to severe malarial anemia and longitudinal all-cause mortality. Hum Genet 2012; 131: 1375-1391.
148. Luty AJ, Lell B, Schmidt-Ott R, etal. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999; 179: 980-988.
149. John CC, Moormann AM, Sumba PO, etal. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004; 72: 5135-5142.
150. Reece WH, Pinder M, Gothard PK, etal. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10: 406-410.
151. Boyle MJ, Jagannathan P, Bowen K, etal. Effector phenotype of Plasmodium falciparum-specific CD4+ T cells is influenced by both age and transmission intensity in naturally exposed populations. J Infect Dis 2015; 212: 416-425.